A personalized mRNA melanoma treatment cut recurrence risk 42%
In a Phase 3 trial, adding investigational intismeran autogene to Keytruda cut melanoma recurrence or death by 42%. Inova Schar was a top-enrolling site. The drug is not FDA-approved.
Read the original
The reporting lives at Inova Newsroom. Our summary is checked against it, and we link it on every story.
Inova Schar, in the Fairfax and Falls Church area, was a top-enrolling site for INTerpath-001, a Phase 3 study in melanoma. Adding the investigational treatment intismeran autogene to the immunotherapy Keytruda cut the risk of recurrence or death by 42% compared with Keytruda alone, Inova reported.
At two years, 82.2% of patients on the combination were cancer-free, versus 70% on Keytruda alone. The treatment is not FDA-approved. Overall survival is still maturing, so this result is about recurrence, not a finished survival verdict and not a cure.
Fairfax, VirginiaMedical researchCancer supportPublic healthGood news on November 4
More good news
Other stories in the same neighborhood of kindness.
Health & TechKentucky's first engineered T-cell treatment for a rare sarcoma is given in Lexington
UK Markey Cancer Center administered Kentucky's first TECELRA treatment, an FDA-approved therapy that uses a patient's own genetically engineered T cells for synovial sarcoma. Care no longer requires a trip to one of a few distant centers.
Verified · University of Kentucky College of Medicine
HeroesGalax firefighters got a hunter out of a tree, then drove his wife to him
A tree stand collapsed and left a hunter hanging above Cranberry Road. Firefighters, deputies, and a rescue squad brought him down. Crews later drove his wife to the hospital because she could not drive.
Verified · WFXR
Health & TechGenetic testing led a Michigan man to a drug that stopped his pancreatitis attacks
After genetic testing found a rare triglyceride disorder, a Michigan man entered a trial of Tryngolza, approved by the FDA in June 2026. Michigan Medicine reports that decades of pancreatitis attacks then stopped. That is his course, not a result for every patient.
Verified · Michigan Medicine